Theriva Biologics (TOVX) Tax Provisions (2022 - 2023)
Theriva Biologics (TOVX) posted quarterly Tax Provisions of $684000.0 for Q4 2023, down 21.29% year-over-year from $869000.0 in Q4 2022, and up 229.79% quarter-over-quarter from -$527000.0 in Q3 2023.
Theriva Biologics (TOVX) Tax Provisions (2022 - 2023) Analysis & Trends
Theriva Biologics (TOVX) has reported Tax Provisions for 2 consecutive years, with $684000.0 the latest figure, recorded in Q4 2023.
- In Q4 2023, Tax Provisions fell 21.29% year-over-year to $684000.0; the TTM figure through Dec 2023 stood at -$532000.0 (down 26700.0% YoY), while the FY2025 annual figure was -$5.0 million, up 7.46% from the prior year.
- Tax Provisions advanced to $684000.0 in Q4 2023 per TOVX's latest filing, from -$527000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $869000.0 in Q4 2022 and bottomed at -$532000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.31 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -90.33 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.90 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 684,000.00 |
| Sep 30, 2023 | -527,000.00 |
| Jun 30, 2023 | -359,000.00 |
| Mar 31, 2023 | -330,000.00 |
| Dec 31, 2022 | 869,000.00 |
| Sep 30, 2022 | -335,000.00 |
| Jun 30, 2022 | -532,000.00 |